The United States remains one of the rare — and certainly the largest — pharmacuetical markets where government has refused to step in to curb pricing and other practices. Defenders of these practices point to the ideological instruction of shareholder value extremism: we must have free markets in which companies use profits and capital to innovate through research and development that, in turn, bring us ever new and more effective pharmaceuticals. The problem, of course, is when any single answer — in this case profits and shareholder value — is repeatedly used like a catechism without reference to it’s actual, fact based effects, even the constructive aspects become emptied of all reason, all possibility.
Should we construct our affairs so that pharmaceutical companies make profits and offer an attractive return to those who provide them capital?
Should we construct our affairs so that pharmaceutical companies drive profitability through kick-back like rewards to doctors who promote their high priced drugs, research and development trials conducted without oversight by independent agencies with sufficient resources to maintain objectivity, campaign funding provided to politicians (who declare themselves anti-science) in exchange for extending legalized monopolies needed to support high prices, product development processes that favor marginal advances on existing drugs over fundamentally new drugs (including life-style drugs instead of life-saving drugs), marketing and advertising campaigns that draw attention toward life-style and away from real need, and, finally, legislation that sets up complexly regulated distribution of drugs to older folks who neither themselves (nor their adult children) can even ever hope to understand — and all because each and every one of these practices and more help pharmaceutical companies do in the United States what they cannot do elsewhere: make unsustainable profits?
Should we continue to allow all of these usurious and unethical practices?
The free market crowd of zealots have become so detached from the facts on the ground about how markets actually operate that it comes as no surprise that Big Pharma is gearing up to fight against allowing for the free market importation of lower priced drugs from Canada.
Here’s the problem. If you’re an executive in a Big Pharma company, you know that the United States market is your last, best hope for sustaining unethcially high prices and shareholder value. Why? Because other markets are now ‘off limits’ to such practices because the governments in those marekts have chosen to blend their concern for Big Pharma profitability with their concern for the health and well being of all of their citizens (not just the top 10%).
For the red meat eating ideologues out there, please re-read: these governments blend their concern for profits and people. Blend. They do not prevent or advocate or wish that Big Pharma become indigent groups operating at unsustainable losses.
No. They wish for and hope and listen to reason to help Big Pharma and all private sector companies make profits — reasonable and sustainable profits. Because that’s how markets work.
But, these other governments — unlike the government of the United States — have said “No” to single answer, shareholder value extremisim. They know that this form of extortion is no more sustainable than continual, persistent losses.
So, if you’re a Big Pharma exec and you look at the markets around the world and you see that, for the most part, your profits will be hemmed in except for one — the US — then what do you do?
You put the peddle to the metal in the US and do whatever it takes to drive as much profitablity as possible out of this last ‘frontier’. Do the math! If you have 10 markets and 9 of them — at best — would produce, say, 10% return on investment while your financial markets are ‘demanding’ you maintain 25% in total — then you better get a heckuva lot higher profitability out of that 10th market if you hope to make the total performance meet these expectations.
So, when a mid-term election shifts Congress from R to D, and the D group knows there’s not much reality left to what we used to refer to as ‘middle class’ — quick fact: the top 1% in this nation have 40% of the assets and they can definitely afford the high prices of Big Pharma’s US market drugs while the lowest 60% of families have 1% of the assets and cannot — and this D group identifies the free market idea of importing lower priced drugs — well then the ‘free market’ Rs and their Big Pharma paymasters are going to go to work quickly to ensure that free market thinking like the D’s offer do not imperil the ‘free market’ profits of the status quo.